Business
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway in
About this update from Cabaletta Bio, Inc.
[{"type":"image","alt":"Cabaletta Bio","displaySize":"","headline":null,"caption":"Cabaletta Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hszKHjsTAmj809exeTCP.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de","width":300,"height":40}},"lazy":false},{"type":"text","content":"– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –","length":95,"tagName":"p"},{"type":"text","content":"– Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 –","length":257,"tagName":"p"},{"type":"text","content":"– Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June –","length":126,"tagName":"p"},{"type":"text","content":"– Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 –","length":105,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","length":390,"tagName":"p"},{"type":"text","content":"“We are looking forward to meeting with the FDA to align on registrational trial designs in myositis, which affects approximately 70,000 patients in the U.S., by leveraging our emerging clinical data and our efficient development strategy. Since presenting clinical and translational data from the RESET program demonstrating that a single weight-based dose of rese-cel was able to provide potentially transformative clinical responses after discontinuation of all immunosuppressants and while off or tapering off steroids, we have seen robust physician and patient interest in the RESET clinical progr...